Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Treasury Shares (2023 - 2026)

Sagimet Biosciences' Treasury Shares history spans 4 years, with the latest figure at $1.1 million for Q1 2026.

  • Quarterly Treasury Shares rose 2.61% to $1.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Mar 2026, up 2.61% year-over-year, with the annual reading at $830077.0 for FY2025, 1.69% down from the prior year.
  • Treasury Shares came in at $1.1 million for Q1 2026, up from $830077.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.1 million in Q4 2023 to a low of $816937.0 in Q3 2025.
  • The 4-year median for Treasury Shares is $1.1 million (2025), against an average of $1.0 million.
  • Year-over-year, Treasury Shares dropped 25.43% in 2024 and then grew 2.61% in 2026.
  • Sagimet Biosciences' Treasury Shares stood at $1.1 million in 2023, then decreased by 25.43% to $844382.0 in 2024, then dropped by 1.69% to $830077.0 in 2025, then surged by 35.78% to $1.1 million in 2026.
  • Per Business Quant, the three most recent readings for SGMT's Treasury Shares are $1.1 million (Q1 2026), $830077.0 (Q4 2025), and $816937.0 (Q3 2025).